REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
5

Thymosin Alpha-1 immune protocol

Spencer Dawson·22 days ago
Looking for input from experienced users on this topic. I have done a lot of reading but wanted to get real-world perspectives from people who have actually tried different approaches. What has worked best for you?

Comments (7)

Petra HutchinsonDEMO·2 months ago

How long did it take before you noticed the first changes? I am on week 2 and wondering if I am being too impatient.

2
Heath ForbesDEMO·about 2 months ago

How long did it take before you noticed the first changes? I am on week 2 and wondering if I am being too impatient.

2
Tate GrantDEMO·about 1 month ago

How long did it take before you noticed the first changes? I am on week 2 and wondering if I am being too impatient.

2
Nico ChangDEMO·22 days ago

How long did it take before you noticed the first changes? I am on week 2 and wondering if I am being too impatient.

2
Harley AdamsDEMO·21 days ago

TA1 has probably the strongest clinical evidence of any peptide discussed on this forum. It is approved as a drug in multiple countries for hepatitis and immune deficiency. The 1.6mg subQ dose 2x/week is the standard clinical protocol and a great starting point.

0
Robin AshfordDEMO·20 days ago

I ran TA1 through an entire cold and flu season. Zero infections when my household had three rounds of illness pass through. Could be coincidence but my NK cell count on blood work went from low-normal to mid-range during the protocol.

0
Ashton WhitfieldDEMO·19 days ago

The mechanism is immunomodulatory rather than immunostimulatory which is an important distinction. It should not theoretically cause autoimmune flares the way some immune boosters can. Has anyone with autoimmune conditions used TA1 safely?

0

Sign in to comment.